MedTrace Logo

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

NCT02847702 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2017-11-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of VM902A twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.

Conditions

  • Osteoarthritis Pain of the Knee

Interventions

DRUG

VM902A 200-mg Capsules

Taken orally with food twice daily

DRUG

VM902A 400-mg Capsules

Taken orally with food twice daily

DRUG

Naproxen 500-mg Capsules

Taken orally with food twice daily

DRUG

Placebo

Capsules to match VM902A and/or naproxen taken orally with food twice daily

Sponsors & Collaborators

  • Purdue Pharma LP

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2016-11-22
Completion
2016-11-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02847702 on ClinicalTrials.gov